CU6 — Clarity Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$695.59m
- AU$517.34m
Brief: Clarity Pharmaceuticals Says FDA Gave Positive Feedback On Phase III Trial For Cu-Sar-Bispsma
Brief: Clarity Pharmaceuticals Enters Clinical Manufacturing Agreement With Spectronrx
Australia's Clarity Pharma hits record high on upbeat revenue, trial progression
Brief: Clarity Pharmaceuticals Says FDA Fast Track Designation For 64Cu-Sar-Bispsma
Brief: Clarity Pharmaceuticals Signs Supply Agreement With Terrapower Isotopes
Brief: Clarity Pharmaceuticals Confirms No Supply Disruptions For Clinical Trials
Australia's Clarity Pharmaceuticals hits record high on copper supply deal
Brief: Clarity Pharmaceuticals Says Agreement With SpectronRx For Production Of Cu-64
Brief: Clarity Pharmaceuticals Enters Clinical Supply Agreement
Brief: Clarity Pharmaceuticals Launches A$121 Million Equity Raise
Brief: Clarity Pharmaceuticals Seeks Trading Halt
Brief: Clarity's Theranostic Prostate Cancer Trial Advances To Multi-Dose Phase
Brief: Clarity Pharmaceuticals Says Additional COBRA Results For SAR-bisPSMA Detects Lesions In 2-millimetre Range
Brief: Clarity Pharmaceuticals Posts HY Loss Attributable A$17.2 Million
Australia's Clarity has promising start to prostate cancer trial- Jefferies
Brief: Clarity Pharmaceuticals Says Phase Iii Clarify Trial In Prostate Cancer Commences
Australia's Clarity Pharmaceuticals at over 2-year high as clinical trial begins
Brief: Clarity Pharmaceuticals Posts Loss For The Year A$24.6 Mln
Brief: Clarity Pharmaceuticals Announce Exclusive License From Memorial Sloan Kettering Cancer Center